ClinicalTrials.gg
Not yet recruitingNCT06913036Updated Apr 6, 2025

Myocene Sensivity to Cycling Intensities

An interventional study of Low-frequency fatigue - Myocene in Fatigue Intensity, sponsored by University of Maia. Not yet recruiting. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by University of Maia · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 35 Years
Sex
Male
01

Study summary

This study aims to address this gap by assessing LFF following different efforts in cycling, aiming to identify a pattern. Also, we expect that this study helps to clarify to which efforts (prolonged vs short) are more likely to trigger substantial changes in LFF responses.

02

Conditions studied

  • Fatigue Intensity

Browse trials for

03

In context

Fatigue

2,234 studies on the registry are indexed under Fatigue; 430 are open to participants now.

This study's planned enrollment of 20 is below the median of 54 across 1,762 interventional studies indexed under Fatigue.

Browse Fatigue studies →

Lead sponsor

University of Maia is the lead sponsor of 21 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Road cyclists

Exclusion criteria

Exclusion Criteria:

  • Injured or recently injured participants
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    4 minutes all-out

    4 minute time trial all-out

    Device: Low-frequency fatigue - Myocene

  • Experimental
    30 minute all-out

    30 minute cycling all-out

    Device: Low-frequency fatigue - Myocene

Interventions

  • DeviceLow-frequency fatigue - Myocene

    Low frequency fatigue will be measured using Myocene

06

What researchers measure

Primary outcomes

  1. low-frequency fatigue

    Low-frequency fatigue assessed using Myocene software, which computes the median value of the ratio between high and low frequency stimulations

    Time frame: Baseline, 30 minutes post, 24 hours post

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for May 2025, 1 month later.

Of 937 non-industry interventional studies with no phase under Fatigue, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 1 month is below that.

Counting every sponsor, half of 990 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Apr 6, 2025
StartEst.
Apr 2025
Primary completionEst.
May 2025
CompletionEst.
Jul 2025
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06913036
Lead sponsor
University of Maia
Responsible party
Filipe Silvano Pinto Maia (Principal Investigator, University of Maia) — Principal investigator
First posted
Apr 6, 2025
Start date
Apr 2025 (estimated)
Primary completion
May 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Apr 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion